ASCO-GI – some shine comes off Astra’s Emerald
The first-line liver cancer Emerald-1 trial is positive, but only up to a point.
ASCO-GI – another surprising TIGIT success?
Skyscraper-08 yields a positive result that – with caveats – looks decent on a cross-trial basis too.
Two allogeneic cell therapy switches in a day
Allogene joins Adicet in going back to the drawing board and scrapping trials in late-line aggressive lymphoma.
Astra scoops JP Morgan
Acquiring Gracell at an 86% premium raises hopes that the biotech markets are bottoming out after a turbulent two years.
Another setback for Opdualag's post-melanoma plan
The latest failure, in colorectal cancer, follows a recent disappointment in second-line liver.
